• Lung
    Categories: , ,

    MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

    17 Mar 2022

  • Lung
    Categories: ,

    KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

    10 Jan 2022

  • Categories: , ,

    New results from immunotherapy trials from the EORTC gynaecological and lung cancer groups presented at ESMO 2021

    20 Sep 2021

  • lung-x-ray
    Categories: , ,

    PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study

    20 Jan 2021

  • Benjamin Besse - ESMO 2020
    Categories: ,

    New Data Gives Hope to Small Cell Lung Cancer Patients

    18 Sep 2020

  • Lung
    Categories: , ,

    Quality of life in lung cancer – EORTC brings the measurements up to date

    24 Mar 2020

  • lung-x-ray
    Categories: ,

    PRESS RELEASE: Inivata and the European Organisation for Research and Treatment of Cancer (EORTC) collaborate in Phase II NSCLC study

    29 Oct 2019

  • Anne-Marie Dingemans
    Categories: ,

    EORTC brings together experts from medical societies to compile a consensus definition for synchronous oligometastatic non small cell lung cancer

    18 Sep 2019